With 0.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $177.99 whereas the lowest price it dropped to was $172.67. The 52-week range on ONC shows that it touched its highest point at $248.16 and its lowest point at $126.97 during that stretch. It currently has a 1-year price target of $287.46. Beta for the stock currently stands at 0.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ONC was down-trending over the past week, with a drop of -3.70%, but this was down by -13.49% over a month. Three-month performance dropped to -24.44% while six-month performance rose 21.80%. The stock gained 3.70% in the past year, while it has lost -3.70% so far this year. A look at the trailing 12-month EPS for ONC yields -8.24 with Next year EPS estimates of -0.70. For the next quarter, that number is -0.92. This implies an EPS growth rate of 36.32% for this year and 86.97% for next year.
Float and Shares Shorts:
At present, 97.25 million ONC shares are outstanding with a float of 96.23 million shares on hand for trading. On 2024-12-13, short shares totaled 1.38 million, which was 128.999995 higher than short shares on 1731628800. In addition to Mr. John V. Oyler as the firm’s Co-Founder, Executive Chairman & CEO, Dr. Xiaobin Wu Ph.D. serves as its President & COO.
Institutional Ownership:
Through their ownership of 0.46887 of ONC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ONC reported revenue of $1001599000.0 and operating income of -$120265000.0. The EBITDA in the recently reported quarter was -$48973000.0 and diluted EPS was -$1.17.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ONC analysts setting a high price target of 376.0 and a low target of 207.0, the average target price over the next 12 months is 280.92477. Based on these targets, ONC could surge 111.38% to reach the target high and rise by 16.37% to reach the target low. Reaching the average price target will result in a growth of 57.93% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
